Immunotherapy is currently one of the most promising treatment options for malignant melanoma[1].To uncover new immunological targets for future treatment approaches,single-cell transcriptomic and epigenomic analyses ...Immunotherapy is currently one of the most promising treatment options for malignant melanoma[1].To uncover new immunological targets for future treatment approaches,single-cell transcriptomic and epigenomic analyses were performed on human primary melanoma(MM)and melanocytic nevus(Nev)samples(Figure 1A).展开更多
基金supported by the Deutsche Forschungsgemeinschaft(DFG)(German Research Foundation,grant numbers:KU 1320/10-1 and HO 6586/1-1,and SFB1430,project 424228829)the Sachsische Aufbaubank(grant number:10071450).
文摘Immunotherapy is currently one of the most promising treatment options for malignant melanoma[1].To uncover new immunological targets for future treatment approaches,single-cell transcriptomic and epigenomic analyses were performed on human primary melanoma(MM)and melanocytic nevus(Nev)samples(Figure 1A).
